Patterns of antiseizure medication utilization in the Human Epilepsy Project

Area of Science:

• Neurology
• Clinical Pharmacology

Background:

• Focal epilepsy diagnosis necessitates effective antiseizure medication (ASM) management.
• Initial treatment often involves ASM monotherapy, but long-term adherence and efficacy vary.
• Understanding the natural history of ASM use is crucial for optimizing patient outcomes.

Purpose of the Study:

• To investigate the long-term outcomes of ASM monotherapy in newly diagnosed focal epilepsy patients.
• To analyze patterns of ASM use, including transitions to sequential monotherapy or polytherapy.
• To compare the duration of initial monotherapy for commonly prescribed ASMs.

Main Methods:

• Analysis of data from the Human Epilepsy Project, including 443 newly diagnosed focal epilepsy patients.
• Classification of patients into monotherapy, sequential monotherapy, and polytherapy groups.
• Utilizing a Cox proportional hazards model to assess differences in the duration of initial ASM monotherapy.

Main Results:

• 36.3% of patients remained on their initial ASM monotherapy, with a median duration of 1.9 years.
• Levetiracetam was the most common initial ASM (57.3%), followed by lamotrigine (17.4%).
• Patients on lamotrigine stayed significantly longer (median 3.1 years) compared to levetiracetam (median 1.5 years).

Conclusions:

• Slightly over one-third of focal epilepsy patients maintain initial ASM monotherapy.
• Nearly 60% of patients not staying on initial monotherapy switch to sequential monotherapy, while 40% move to polytherapy.
• Lamotrigine demonstrates a longer duration of use as initial monotherapy compared to levetiracetam.